Dec 10 (Reuters) - Ligand Pharmaceuticals LGND.O:
LIGAND HOSTS 2024 INVESTOR AND ANALYST DAY AND INTRODUCES 2025 GUIDANCE
LIGAND PHARMACEUTICALS INC -2025 FULL YEAR REVENUE GUIDANCE OF $180 MILLION TO $200 MILLION
LIGAND PHARMACEUTICALS INC - OUTLOOK 2025 FULL YEAR CORE ADJUSTED EARNINGS PER DILUTED SHARE OF $6.00 TO $6.25
LIGAND PHARMACEUTICALS INC -WILL REITERATE ITS 2024 GUIDANCE OUTLINED IN NOVEMBER
Source text: ID:nBwcgVMZNa
Further company coverage: LGND.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。